Myofasziale Schmerzsyndrome

Zusammenfassung

Myofasziale Schmerzsyndrome haben eine hohe Bedeutung in der Differenzialdiagnose von Muskelschmerzen. Obwohl sie eine der häufigsten Ursachen akuter und chronischer muskuloskelettaler Schmerzen darstellen, werden sie zu selten differenzialdiagnostisch bedacht, teils auch aufgrund mangelnden Wissens über strukturierte therapeutische Strategien. Diagnostisch steht der klinische Befund im Vordergrund. Therapeutisch führend sind physikalisch-manuelle Techniken, ergänzt durch invasive Techniken wie die trockene Nadelung und Triggerpunktinjektionen. Die Identifizierung und Ausschaltung aktivierender und aufrechterhaltender Faktoren haben hohe Bedeutung für den Therapieerfolg. Der temporäre Einsatz oraler Medikation mit Muskelrelaxanzien, ggf. auch Analgetika und nichtsteroidalen Antirheumatika, runden das therapeutischen Konzept ab. Für chronische therapierefraktäre Syndrome stehen im Einzelfall und unter individueller Abwägung Injektionen mit Botulinumtoxin A und ggf. auch der Einsatz von Stoßwellen als therapeutische Option zur Verfügung.

Abstract

Myofascial pain syndromes are important in the differential diagnosis of myalgias. Despite their high prevalance in both acute and chronic musculoskeletal pain, they often remain unconsidered partly due to a lack of knowledge about systematic therapeutic strategies. Clinically, the manual examination is essential. Regarding therapy, main elements are manual physical therapies complemented by invasive techniques like dry needling and trigger point injections. Identification and elimination of activating or perpetuating factors are highly important for therapeutic success. The temporary use of oral drugs like muscle relaxants, analgetics, and NSAID completes the therapeutic concept. In individual cases, chronic therapy-resistant syndromes can be treated with additional injections of botulinum toxin A and by shock wave therapy, respectively, as a therapeutic off-label option.

myofaszialer Schmerz - Triggerpunkte - Muskelschmerz

myofascial pain - trigger points - muscle pain

Literatur

• 1 Fishbain DA, Goldberg M, Meagher BR. et al . Male and female chronic pain patients categorized by DSM-III psychiatric diagnostic criteria.  Pain. 1986;  26 181-197
• 2 Fricton JR, Kroening R, Haley D. et al . Myofascial pain syndrome of the head and neck: a review of clinical characteristics of 164 patients.  Oral Surg Oral Med Oral Pathol. 1985;  60 615-623
• 3 Evans RW. Some observations on whiplash injuries.  Neurol Clin. 1992;  10 975-997
• 4 Simons DG, Travell J. Myofascial Pain and Dysfunction. The Trigger Point Manual. 2nd ed Baltimore: Williams & Wilkins 1999
• 5 Gerwin RD, Shannon S, Hong CZ. et al . Interrater reliability in myofascial trigger point examination.  Pain. 1997;  69 65-73
• 6 Tough EA, White AR, Richards S. et al . Variability of criteria used to diagnose myofascial trigger point pain syndrome–evidence from a review of the literature.  Clin J Pain. 2007;  23 278-286
• 7 Simons DG, Stolov WC. Microscopic features and transient contraction of palpable bands in canine muscle.  Am J Phys Med. 1976;  55 65-88
• 8 Reilich P, Pongratz D. Myofascial pain syndrome. In: Jost WH, ed Botulinum toxin in painful diseases. Basel: Karger 2003: 23-41
• 9 Gerwin RD, Dommerholt J, Shah JP. An expansion of Simons' integrated hypothesis of trigger point formation.  Curr Pain Headache Rep. 2004;  8 468-475
• 10 Shah JP, Gilliams EA. Uncovering the biochemical milieu of myofascial trigger points using in vivo microdialysis: an application of muscle pain concepts to myofascial pain syndrome.  J Bodyw Mov Ther. 2008;  12 371-384
• 11 Shah JP, Danoff JV, Desai MJ. et al . Biochemicals associated with pain and inflammation are elevated in sites near to and remote from active myofascial trigger points.  Arch Phys Med Rehabil. 2008;  89 16-23
• 12 Hong CZ, Simons DG. Pathophysiologic and electrophysiologic mechanisms of myofascial trigger points.  Arch Phys Med Rehabil. 1998;  79 863-872
• 13 Kuan TS, Hsieh YL, Chen SM. et al . The myofascial trigger point region: correlation between the degree of irritability and the prevalence of endplate noise.  Am J Phys Med Rehabil. 2007;  86 183-189
• 14 Brückle W, Suckfüll M, Fleckenstein W. et al . Tissue pO2 measurement in taut back musculature (m. erector spinae).  Z Rheumatol. 1990;  49 208-216
• 15 Mense S, Simons DG, Russell IJ. Muscle pain: understanding its nature, diagnosis, and treatment. Baltimore: Lippincott Williams & Wilkins 2001
• 16 Grobli C, Dejung B. Non-medical therapy of myofascial pain.  Schmerz. 2003;  17 475-480
• 17 Simons DG, Travell JG. Myofascial origins of low back pain. 1. Principles of diagnosis and treatment.  Postgrad Med. 1983;  73 66 68-70 73 passim
• 18 Lewit K, Simons DG. Myofascial pain: relief by post-isometric relaxation.  Arch Phys Med Rehabil. 1984;  65 452-456
• 19 Dommerholt J, Bron C, Franssen J. Myofascial trigger points: an evidence-informed review.  J Manual Manipul Ther. 2006;  4 203-221
• 20 Dommerholt J, Mayoral del Moral O, Grobli C. Trigger Point Dry Needling.  J Manual Manipul Ther. 2006;  4 E70-E87
• 21 Ettlin T. Trigger point injection treatment with the 5-HT3 receptor antagonist tropisetron in patients with late whiplash-associated disorder. First results of a multiple case study.  Scand J Rheumatol Suppl. 2004;  33 (Suppl. 119) 49-50
• 22 Müller W, Stratz T. Local treatment of tendinopathies and myofascial pain syndromes with the 5-HT3 receptor antagonist tropisetron.  Scand J Rheumatol Suppl. 2004;  33 (Suppl. 119) 44-48
• 23 Kamanli A, Kaya A, Ardicoglu O. et al . Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome.  Rheumatol Int. 2005;  25 604-611
• 24 Venancio Rde A, Alencar FG Jr, Zamperini C. Botulinum toxin, lidocaine, and dry-needling injections in patients with myofascial pain and headaches.  Cranio. 2009;  27 46-53
• 25 Göbel H, Heinze A, Reichel G. et al . Efficacy and safety of a single botulinum type A toxin complex treatment (Dysport) for the relief of upper back myofascial pain syndrome: results from a randomized double-blind placebo-controlled multicentre study.  Pain. 2006;  125 82-88
• 26 Ho KY, Tan KH. Botulinum toxin A for myofascial trigger point injection: a qualitative systematic review.  Eur J Pain. 2007;  11 519-527
• 27 Reilich P, Fheodoroff K, Kern U. et al . Consensus statement: botulinum toxin in myofascial [corrected] pain.  J Neurol. 2004;  251 ((Suppl 1)) I36-I38
• 28 Reilich P, Schoser BG. Accuracy of botulinum toxin injections in myofascial pain.  Response to Gobel et al.  Pain. 2006;  125 82-88 Pain 2007; 130: 299; author reply 299-300 

Korrespondenzadresse